RESEARCH
Dexamethasone: New Study Shows Promising Results for COVID-19 Patients .
Dexamethasone has drawn renewed attention after evidence from ARDS research and the large RECOVERY trial suggested meaningful benefits in severe respiratory illness. Earlier ARDS studies showed steroids could ease inflammation and shorten time on ventilation, but effects on survival were unclear. The RECOVERY trial shifted that view by demonstrating lower mortality in hospitalized COVID-19 patients needing oxygen or mechanical ventilation when treated with low-dose dexamethasone. Benefits did not extend to patients without respiratory support, and important cautions remain. Past SARS experience linked high-dose or prolonged steroid use to complications such as avascular necrosis, underscoring the need for careful dosing, short treatment courses, and thoughtful follow-up when steroids are used in acute viral illness.
Already have an account? Log in
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
